Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population Pharmacokinetics of Meropenem Across the Adult Lifespan.
Boutzoukas AE, Balevic SJ, Hemmersbach-Miller M, Winokur PL, Gu K, Chan AW, Cohen-Wolkowiez M, Conrad T, An G, Kirkpatrick CMJ, Swamy GK, Walter EB, Schmader KE, Landersdorfer CB. Boutzoukas AE, et al. Among authors: gu k. Clin Pharmacokinet. 2024 Dec 16. doi: 10.1007/s40262-024-01465-1. Online ahead of print. Clin Pharmacokinet. 2024. PMID: 39681779
Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.
Qiu MZ, Bai Y, Wang J, Gu K, Yang M, He Y, Yi C, Jin Y, Liu B, Wang F, Chen YK, Dai W, Jiang Y, Huang C, Xu RH, Luo HY. Qiu MZ, et al. Among authors: gu k. Signal Transduct Target Ther. 2024 Dec 16;9(1):349. doi: 10.1038/s41392-024-02063-0. Signal Transduct Target Ther. 2024. PMID: 39676137 Free PMC article. Clinical Trial.
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.
Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, Wang H, Yin Y, Wang X, Zhou X, Wang Y, Sun G, Wang J, Zhang L, Yang J, Qian J, Yan M, Liu X, Yi T, Cheng Y, Li M, Zang A, Wang S, Wang C, Wu X, Cheng J, Li H, Lin Y, Geng C, Gu K, Xie C, Xiong H, Wu X, Yang J, Li Q, Chen Y, Li F, Zhang A, Zhang Y, Wu Y, Nie J, Liu Q, Wang K, Mo X, Chen L, Pan Y, Fu P, Zhang H, Pang D, Sheng Y, Han Y, Wang H, Cang S, Luo X, Yu W, Deng R, Yang C, Keegan P. Jiang Z, et al. Among authors: gu k. Future Oncol. 2024 Dec 4:1-9. doi: 10.1080/14796694.2024.2430106. Online ahead of print. Future Oncol. 2024. PMID: 39628303
Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients.
Reeder JA, Creech CB, Nation RL, Gu K, Nalbant D, Wu N, Jimenez-Truque N, Fissell W, Rolsma SL, Fishbane N, Kirkpatrick CMJ, Patel PC, Watanabe A, Landersdorfer CB, Winokur P, An G. Reeder JA, et al. Among authors: gu k. J Clin Pharmacol. 2024 Dec 3. doi: 10.1002/jcph.6161. Online ahead of print. J Clin Pharmacol. 2024. PMID: 39628093
1,100 results